---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-007941"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2024-01-26T23:59:59+00:00"
generated_at: "2026-06-06T16:41:06.108978+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# SAB Biotherapeutics signs $20M ATM equity offering with Cantor Fitzgerald

## Summary
- ATM agreement allows sale of up to $20M of common stock through Cantor as sales agent.
- Agent will receive 3.0% of gross proceeds per sale; no minimum obligation to sell.
- Net proceeds to fund pipeline development and general corporate/working capital.
- Agreement is terminable by either party on ten days' notice.

## SEC filing metadata
- accession: 0000950170-24-007941
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2024-01-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000095017024007941/0000950170-24-007941-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000095017024007941/sabs-20240126.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-007941
- JSON: https://secwatch.observer/filing/0000950170-24-007941.json
- Plain text: https://secwatch.observer/filing/0000950170-24-007941.txt

## Key facts
- Material Agreements
  SAB Biotherapeutics, Inc. entered into Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald & Co. valued at $20,000,000 (effective 2024-01-26).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Cantor Fitzgerald & Co.
  - Value: $20,000,000
  - Effective: 2024-01-26
  source text: On January 26, 2024, SAB Biotherapeutics, Inc. (the “Company”) entered into a Controlled Equity OfferingSM Sales Agreement (the “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”). In accordance with the terms of the Agreement, pursuant to the Prospectus Supplement (as defined below), the Company may offer and sell from time to time through or to the Agent, as sales agent, the Company’s common stock, par value $0.0001 per share, having an aggregate offering price of up to $20,000,000 (the “Placement Shares”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1833214/000095017024007941/0000950170-24-007941-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.